SANOFI EFC17504 The purpose of this study is to determine the efficacy of frexalimab in delaying the disability progression and the safety in participants with non-relapsing secondary progressive multiple sclerosis. Inclusion Criteria: 18-60 years of age, a diagnosis of non-relapsing secondary progressive multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years, without clinical […]
PIPELINE/CONTINUUM VISTA This is a randomized, double-blind study of PIPE-307 or placebo to see if it can help patients with relapsing-remitting multiple sclerosis. Inclusion Criteria: 18-50 years of age, a diagnosis of relapsing-remitting multiple sclerosis Stable immunomodulatory treatment Diagnosed within the last 10 years Without clinical MS relapse or treatment with corticosteroids within last 6
PIPELINE/CONTINUUM VISTA Read More »
INDIVIOR INDV-6000-406 This study will provide the opportunity to generate data on the long-term use of SUBLOCADE under real-world conditions, and to observe enduring changes in lifestyle, health, and sociodemographic factors that are part of the recovery process. Inclusion Criteria: At least 18 years of age, has initiated treatment with SUBLOCADE within the last 3
INDIVIOR INDV-6000-406 Read More »
JAZZ PATAGONIA (Parkinson’s Disease) This is a 17-week double-blind, placebo-controlled, randomized, flexible-dosing, parallel-group, multicenter study designed to evaluate the efficacy and safety of suvecaltamide for the treatment of moderate to severe residual tremor in adult participants with Parkinson’s disease (PD). The target population represents participants who have tremor that is not adequately controlled by PD
IGC PHARMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease. Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What to
ACADIA RADIANT (Alzheimer’s Disease Psychosis) In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis. Inclusion Criteria: 50 years to 95 years of age Meets clinical criteria for possible or probable Alzheimer’s Disease Psychotic symptoms (hallucinations or delusions) for at least 2 months Availability of a designated study partner/caregiver What to Expect
SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria: 50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study
SUVEN CTP3S1502HT6 Read More »
BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on
ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria: 50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study
0XA1 Study This study will test if an investigational medicine (a Medicine being studied) could safely reduce weight in people with obesity or overweight. Inclusion Criteria: Aged 18 to 75 years old Do NOT have diabetes have obesity (BMI of 30 or more) or have overweight (BMI of 27 or more) and a health condition:
